WC
AXDX

Wexford Capital’s Accelerate Diagnostics AXDX Stock Holding History

Wexford Capital’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-748
Closed -$57K – 210
2020
Q4 		$57K Buy
748
+548
+274% +$49.1K 0.01% 165
2020
Q3 		$21K Hold
200
– – 0.01% 168
2020
Q2 		$30K Buy
+200
New +$19.7K 0.01% 167

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Wexford Capital's AXDX Position: Q1 2021 in Review

Wexford Capital sold out of Accelerate Diagnostics (AXDX) in Q1 2021, closing a stake of 748 shares — an estimated $57K sold.

Wexford Capital first reported a position in AXDX in Q2 2020 and held it in 3 quarters. The position peaked at $57K in Q4 2020. 99 funds tracked by Wall St. Rank hold AXDX as of Q1 2021.

  • Wexford Capital reported no remaining Accelerate Diagnostics position as of Q1 2021 after selling out during the quarter.
  • Wexford Capital sold 748 Accelerate Diagnostics shares in Q1 2021, an estimated $57K.
  • Wexford Capital first reported a position in Accelerate Diagnostics in Q2 2020 and held it in 3 quarters.
  • Wexford Capital's Accelerate Diagnostics position peaked at $57K in Q4 2020.
  • 99 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.